Prime Capital Investment Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Prime Capital Investment Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,499	Closed	-$238K	–	947
2024 Q1	$238K	Buy	3,499 +212	+6%	+$15.2K	﹤0.01%	858
2023 Q4	$206K	Buy	+3,287	New	+$182K	﹤0.01%	873
2021 Q2	–	Sell	-527	Closed	-$64K	–	409
2021 Q1	$64K	Buy	527 +256	+94%	+$38.7K	﹤0.01%	316
2020 Q4	$41K	Buy	271 +45	+20%	+$5.32K	﹤0.01%	340
2020 Q3	$19K	Buy	+226	New	+$20K	﹤0.01%	377

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Prime Capital Investment Advisors's CRSP Position: Q2 2024 in Review

Prime Capital Investment Advisors sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 3,499 shares — an estimated $238K sold.

Prime Capital Investment Advisors first reported a position in CRSP in Q3 2020 and held it in 5 quarters. The position peaked at $238K in Q1 2024. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

Prime Capital Investment Advisors reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
Prime Capital Investment Advisors sold 3,499 CRISPR Therapeutics shares in Q2 2024, an estimated $238K.
Prime Capital Investment Advisors first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 5 quarters.
Prime Capital Investment Advisors's CRISPR Therapeutics position peaked at $238K in Q1 2024.
449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.